Our Blog
Insights on regulatory affairs, quality, pharmacovigilance and RNA technologies from the Molgenium team.
GMP & Quality
Annex 11 and Chapter 4 Are Being Rewritten: How to Prepare Now
By Dr. Mohamad Toutounji
Sep 25, 2026
CMC & Product Development
Analytics Over Trials: The New Biosimilar Pathway and What It Means for CMC
By Dr. Mohamad Toutounji
Sep 22, 2026
Case Studies
From Mock Inspection to Inspection-Ready: A 120-Day Data Integrity Remediation
By Dr. Mohamad Toutounji
Sep 18, 2026
Analytical & QC
Two Years of ICH Q14 and Q2(R2): From One-Off Validation to Analytical Lifecycle
By Dr. Mohamad Toutounji
Sep 15, 2026
AI & Digital Pharma
FDA's First AI Warning Letter and Draft Annex 22: What They Mean for GMP
By Dr. Mohamad Toutounji
Sep 11, 2026